Posters & Publications

SABCS 2025: Liquid Biopsy Tracking of PI3K–mTOR Residual Disease Signatures in Metastatic HER2+ Breast Cancer

SABCS 2025: A Phase 1b, Multi-Centre, Open-Label, Randomized Study to Evaluate the Safety, Tolerability, and Clinical Activity of Combining Paxalisib with Olaparib or Pembrolizumab/Chemotherapy in Patients With Advanced Breast Cancer

Melino et al (2025): Depleting the Action of EZH2 Through PI3K-mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer

15th Biennial Ovarian Cancer Research Symposium: Phase I Study of EVT801, a VEGFR-3 Inhibitor, Shows Promising Clinical Activity in HGS Ovarian Cancer

AACR 2024: EVT801, a Novel Selective VEGFR-3 Inhibitor Targeting Tumour Angiogenesis, Is Pursuing Dose Escalation Stage of Phase I First-In-Human Study

AACR 2024: Biomarkers Analysis on Samples From Patients in EVT801 Clinical Trial: Patient Characterization and Immunomonitoring

ESMO 2023: VEGFR-3 Expression Profiling by Histology and Biomarkers Strategy to Classify Patient Population for the Selective VEGFR-3 Inhibitor EVT801

AACR 2023: VEGFR-3 Signature Expression by Histology to Classify Patient Population for the Selective VEGFR-3 Inhibitor EVT801

International Congress of the Society for Melonoma Research 2022: Genetic Silencing of AKT Induces Melanoma Cell Death

ASCO 2022: Paxalisib in Newly Diagnosed Glioblastoma Patients With Unmethylated MGMT Promoter Status (Final Phase 2 Study Results)

SNO 2020: Interim Results of a Phase 2 Study to Evaluate the PI3K/mTOR Inhibitor Paxalisib (GDC-0084) Given to Newly Diagnosed Glioblastoma Patients With Unmethylated O6-Methylguanine-Methyltransferase Promoter

AACR 2020: Phase 2a study to evaluate the safety, pharmacokinetics, and clinical activity of the PI3K / mTOR inhibitor paxalisib (GDC-0084) given to glioblastoma (GBM) patients with unmethylated MGMT promotor status

ASCO 2020: Phase 2a Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the PI3K / mTOR Inhibitor GDC-0084 Given to Glioblastoma (GBM) Patients with Unmethylated MGMT Promotor Status

Ellingson et al (2020): Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma

Wen et al (2020): First-In-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma

EANO 2019: Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the PI3K / mTOR Inhibitor GDC-0084 Given to Glioblastoma (GBM) Patients with Unmethylated O6-Methylguaninemethyltransferase (MGMT) Promotor Status

Ippen et al (2019): The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases

SNO 2018: Phase 2 Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of PI3K/mTOR Inhibitor GDC-0084 Given to Glioblastoma (GBM) Patients with Unmethylated O6-Methylguanine-Methyltransferase Promoter Status

Salphati et al (2016): Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma

ASCO 2016: A First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma

ASCPT 2016: Clinical Pharmacokinetics and Brain Penetration of GDC-0084, an Oral PI3K/mTOR Inhibitor, in Patients with High-Grade Glioma

Heffron et al (2016): Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR